For those just tuning in to CTIX, here's a quick s

For those just tuning in to CTIX, here's a quick summary of latest developments:

- PR announcement just made that an agreement has been reached to conduct a clinical trial for Prurisol in Europe, a short 30 day trial with a 30 day follow up, a double blind study that clearly shows the confidence the company has in proving quickly that the compound is vastly superior to methotrexate, the current standard of treatment

- Kevetrin phase 1 clinical trial now under way, with dosing of patients continuing as we speak

- Other than the announcement that dosing has started for Kevetrin, relative radio silence out of Dana Farber as they continue to accumulate data from dosing - speculation is that a biomarker announcement may not come for as long as a few weeks - but for now no news is GOOD news

- Kevetrin leukemia trial in Europe is a definitive "go", and the nuts and bolts of the protocol for this trial are also being developed and written as we speak - speculation that this protocol planning wouldn't be progressing unless there was confirmation of Kevetrin initial dosing at Dana Farber having favorable/expected results so far

- Excitement continues to build as we get closer to hearing more info from the Dana Farber Kevetrin trial - lots going on with CTIX, lots of announcements, trial data, and airplay coming our way heading into 2013 : the breakout year for Cellceutix!